Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions
Herbst RS, Aisner DL, Sonett JR, Turk AT, Weintraub JL, Lindeman NI. Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions. Frontiers In Medicine 2021, 7: 562480. PMID: 33553195, PMCID: PMC7859651, DOI: 10.3389/fmed.2020.562480.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerLung cancerAdvanced non-small cell lung cancerGenomic profilingExpert consensus guidanceMultidisciplinary advisory boardAccurate histopathological diagnosisGenomic screening programDrug Administration approvalProto-oncogene tyrosine-protein kinase receptor RetNumber of biomarkersStandard careInvestigational agentsTargetable alterationsHistopathological diagnosisRET fusionsActionable biomarkersAdministration approvalBiomarker testingScreening programSurgical pathologistsSpecific small molecule inhibitorsTreatment selectionBiopsy tissue